Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-0-17-8463-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.22 billion
Profitability
Miscellaneous
Employees3,700
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) released its earnings results on Tuesday, May, 7th. The company reported $1.94 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.73 by $0.21. The firm had revenue of $791 million for the quarter, compared to the consensus estimate of $766.27 million. Mallinckrodt had a positive return on equity of 14.22% and a negative net margin of 118.53%. The company's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.31 EPS. View Mallinckrodt's Earnings History.
When is Mallinckrodt's next earnings date?
What guidance has Mallinckrodt issued on next quarter's earnings?
Mallinckrodt issued an update on its FY19 earnings guidance on Tuesday, May, 7th. The company provided earnings per share (EPS) guidance of $8.30-8.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.21. Mallinckrodt also updated its FY 2019 guidance to $8.30-8.60 EPS.
What price target have analysts set for MNK?
17 equities research analysts have issued 1 year price targets for Mallinckrodt's stock. Their predictions range from $5.00 to $58.00. On average, they expect Mallinckrodt's share price to reach $20.8235 in the next twelve months. This suggests a possible upside of 129.7% from the stock's current price. View Analyst Price Targets for Mallinckrodt.
What is the consensus analysts' recommendation for Mallinckrodt?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 2 sell ratings, 12 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.
What are Wall Street analysts saying about Mallinckrodt stock?
Here are some recent quotes from research analysts about Mallinckrodt stock:
- 1. According to Zacks Investment Research, "Mallinckrodt’s hospital franchise (Inomax and Ofirmev) has gained traction which is positively impacting performance. The spin-off of the generic business appears to be a step in the right direction as this will enable Mallinckrodt to focus better on the branded business, which promises potential. Mallinckrodt has streamlined its business of late to focus better on its innovative medicines and therapies. The company has been involved in quite a few lawsuits for its alleged role in the current opioid epidemic in the United States through its marketing and promotion practices. Shares have outperformed the industry in the last six months. However, pipeline setbacks continue to weigh on the company. The CRL for stannsoporfin was disappointing. Acthar, Mallinckrodt’s largest product, is being impacted by the residual impact of the previously reported patient withdrawal issues." (1/8/2019)
- 2. Mizuho analysts commented, "We reiterate our Neutral rating into what we view as risky read-outs for VTS-270 in Niemann- Pick Type C, and CPP-1X/Sulindac in FAP." (11/6/2018)
- 3. Canaccord Genuity analysts commented, "We were pleasantly surprised by Mallinckrodt’s 2Q/18 beat and raise last week as the story continues to evolve toward higher pipeline science and away from Acthar- related drama. However, with strong momentum behind MNK shares of late, we remain concerned about external forces on Acthar or internal pipeline setbacks potentially squelching momentum in the story." (8/13/2018)
Has Mallinckrodt been receiving favorable news coverage?
News articles about MNK stock have trended somewhat positive recently, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mallinckrodt earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Mallinckrodt.
Are investors shorting Mallinckrodt?
Mallinckrodt saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 33,737,400 shares, an increase of 17.0% from the April 30th total of 28,836,500 shares. Based on an average trading volume of 2,720,000 shares, the days-to-cover ratio is presently 12.4 days. Approximately 41.0% of the shares of the company are short sold. View Mallinckrodt's Current Options Chain.
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Global Blood Therapeutics (GBT), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), Uniqure (QURE), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), The Medicines (MDCO), Reata Pharmaceuticals (RETA), Arrowhead Pharmaceuticals (ARWR), Intercept Pharmaceuticals (ICPT), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), Myokardia (MYOK), Ligand Pharmaceuticals (LGND) and Akcea Therapeutics (AKCA).
What other stocks do shareholders of Mallinckrodt own?
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
- Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
- Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)
- Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
- Mr. Bryan M. Reasons, Chief Financial Officer (Age 52)
Who are Mallinckrodt's major shareholders?
Mallinckrodt's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include LSV Asset Management (4.97%), MERIAN GLOBAL INVESTORS UK Ltd (2.61%), Acadian Asset Management LLC (1.69%), Parametric Portfolio Associates LLC (1.08%), Connor Clark & Lunn Investment Management Ltd. (0.94%) and Jacobs Levy Equity Management Inc. (0.61%). Company insiders that own Mallinckrodt stock include Bryan M Reasons, David R Carlucci, Dr Kneeland Youngblood, James E Flynn, Joann A Reed, Mark Trudeau, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.
Which institutional investors are selling Mallinckrodt stock?
MNK stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Spark Investment Management LLC, Acadian Asset Management LLC, Royce & Associates LP, SG Americas Securities LLC, Commonwealth Bank of Australia, Connor Clark & Lunn Investment Management Ltd. and California Public Employees Retirement System. View Insider Buying and Selling for Mallinckrodt.
Which institutional investors are buying Mallinckrodt stock?
MNK stock was acquired by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Hussman Strategic Advisors Inc., Bank of Montreal Can, 361 Capital LLC, Parametric Portfolio Associates LLC, Raymond James Financial Services Advisors Inc., Nordea Investment Management AB and ClariVest Asset Management LLC. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons, David R Carlucci, Dr Kneeland Youngblood, Joann A Reed, Mark Trudeau, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $9.0650.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $759.74 million and generates $3.22 billion in revenue each year. The company earns $-3,607,000,000.00 in net income (profit) each year or $8.01 on an earnings per share basis. Mallinckrodt employs 3,700 workers across the globe.View Additional Information About Mallinckrodt.
What is Mallinckrodt's official website?
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (NYSE MNK)
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
